Will Glaxo spin off consumer arm to focus on its pharmaceuticals and vaccines?

Philip Hampton, the British drugs giant’s chairman, is reportedly considering the move after talks with major shareholders. Such a shake-up was called for by fund manager Neil Woodford last year.